IMIbrahim T. Mughrabi

Ibrahim T. Mughrabi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ibrahim T. Mughrabi has a total of 105 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Longitudinal Characterization of Compound Action Potentials in Chronic Vagus Nerve Recordings in Mice

    by Shubham Debnath, Ibrahim T. Mughrabi, Todd J. Levy, Fylaktis Fylaktou, Nilay Kumar, Yousef Al-Abed, Stavros Zanos, Theodoros P. Zanos

    The vagus nerve (VN) mediates bidirectional communication between the body and brain to maintain physiological homeostasis; likewise, alterations in ongoing vagal signaling may be indicators of disease and/or contribute to disease pathogenesis. Even though extensively documented in acute experiments, ongoing vagal activity has not been characterized longitudinally, over days or weeks, in mice, a preferred preclinical model. In addition, even though many VN recordings in mice occur during anesthesia, the effects of anesthesia on vagal signaling are unknown. This study uses a chronic implant mouse model to record vagal activity in anesthetized and awake, behaving animals for an average of 10 weeks and up to 6 months. Individual compound action potentials (CAPs) are tracked across multiple days by quantifying comparisons in features, including firing rates, waveform shape, inter-CAP interval histograms, and phase-locking to cardiac and respiratory signals, while demonstrating long-term electrode-nerve interface viability and stable signal-to-noise ratios. Additionally, cytokine challenge experiments produced detectable CAP responses up to 3 months after electrode implantation. Lastly, awake recordings incorporated video analysis to identify and remove motion artifacts to preserve and extract neural and cardiac recordings during daylight in-cage behavior. Results reveal diverse CAP populations with diverse physiological coupling and firing rates modulated by anesthesia. This work highlights the potential of chronic VN recordings to assess long-term changes in vagal activity in health and disease, with implications for the discovery of autonomic markers of disease and closed-loop VNS stimulation strategies.

  • Open Access

    Atom-level backbone engineering preserves peptide function while enhancing stability

    by Mingzhu He, Kai Fan Cheng, Anh Vu, Marcelo D. T. Torres, Stavros Zanos, Ibrahim T Mughrabi, Cesar de la Fuente-Nunez, Yousef Al-Abed

    Peptide therapeutics offer unmatched potency and selectivity but are limited by rapid proteolysis and poor pharmacokinetics. Backbone engineering provides a rational approach to enhance stability while preserving function, yet direct comparisons across strategies remain scarce. Using bradykinin as a model, we systematically evaluated four backbone modifications—D-amino acid substitution, N-methylation, α-methylation, and azapeptide incorporation. Each modification produced distinct outcomes in synthesis, conformation, proteolytic stability, and receptor pharmacology. While D- and N-methyl substitutions yielded high stability, they compromised receptor binding and in vivo function. In contrast, the azapeptide analogue maintained native-like affinity and physiological activity while achieving an enhanced stability profile. These findings highlight the need to balance stability and function in peptide design and position azapeptides as an underexplored class with strong therapeutic potential. More broadly, this study establishes a framework for systematic, data-driven peptide design and optimization.


  • Open Access

    Longitudinal characterization of compound action potentials in chronic vagus nerve recordings in mice

    by Shubham Debnath, Ibrahim T. Mughrabi, Todd J. Levy, Fylaktis Fylaktou, Nilay Kumar, Yousef Al-Abed, Stavros Zanos, Theodoros P. Zanos

    The vagus nerve (VN) mediates bidirectional communication between the body and brain to maintain physiological homeostasis; likewise, alterations in ongoing vagal signaling may be indicators of disease and/or contribute to disease pathogenesis. Even though extensively documented in acute experiments, ongoing vagal activity has not been characterized longitudinally, over days or weeks, in mice, a preferred preclinical model. In addition, even though many VN recordings in mice occur during anesthesia, the effects of anesthesia on vagal signaling are unknown. This study uses a chronic implant mouse model to record vagal activity in anesthetized and awake, behaving animals for an average of 10 weeks and up to 6 months. Individual compound action potentials (CAPs) are tracked across multiple days by quantifying comparisons in features, including firing rates, waveform shape, inter-CAP interval histograms, and phase-locking to cardiac and respiratory signals while demonstrating long-term electrode-nerve interface viability and stable signal-to-noise ratios. Additionally, cytokine challenge experiments produced detectable CAP responses up to 3 months after electrode implantation. Lastly, awake recordings incorporated video analysis to identify and remove motion artifacts to preserve and extract neural and cardiac recordings during behavior. Results reveal diverse CAP populations with diverse physiological coupling and firing rates modulated by anesthesia. This work highlights the potential of chronic VN recordings to assess long-term changes in vagal activity in health and disease, with implications in discovery of autonomic markers of disease and closed-loop VNS stimulation strategies.

  • Open Access

    Protease-Resistant Azapeptide GLP-1 Analogue Improves Metabolic Control in Diet-Induced Obesity

    by Mingzhu He, Kai Fan Cheng, Sonya Vanpatten, Marcelo D. T. Torres, Bayan Al Jabari, Ibrahim T Mughrabi, Borja Ballarín-González, Myoungsun Son, Cesar De La Fuente-Nunez, Yousef Al-Abed

    Peptide therapeutics are limited by rapid proteolysis and short half-lives. Azapeptides, created by replacing one or more α-carbon(s) on the peptide backbone with nitrogen atom(s), offer a strategy to improve peptide stability while preserving functional efficiency, yet their clinical potential has remained underexplored. Herein, we report the design, synthesis, in vitro and in vivo evaluations of azapeptide-based glucagon-like peptide-1 receptor agonists (GLP-1RAs). Using a solid-phase synthesis platform, we generated GLP-1 analogues with aza-substitutions at protease-sensitive residues. The lead analogue, AzaA 8 /R 34 -GLP-1(AzaA8), resisted dipeptidyl peptidase-4 degradation (>24 h), maintained picomolar potency at the GLP-1 receptor (GLP-1R) signaling, and exhibited an extended plasma half-life in mice relative to unmodified controls. In lean mice, AzaA8 improved oral glucose tolerance, and in high-fat diet-induced obese mice, chronic administration reduced body weight, decreased leptin and insulin levels, and enhanced glucose handling without detectable inflammatory adverse effects. These findings demonstrate that a targeted aza-substitution yields a protease-stable, biologically active GLP-1RA with metabolic benefits, establishing azapeptides as a promising scaffold for next-generation incretin-based therapies in diabetes and obesity.


  • Open Access

    Vagus nerve stimulation modulates distinct acetylcholine receptors on B cells and limits the germinal center response

    by Izumi Kurata-Sato, Ibrahim T. Mughrabi, Minakshi Rana, Michael Gerber, Yousef Al-Abed, Barbara Sherry, Stavros Zanos, Betty Diamond

    Acetylcholine is produced in the spleen in response to vagus nerve activation; however, the effects on antibody production have been largely unexplored. Here, we use a chronic vagus nerve stimulation (VNS) mouse model to study the effect of VNS on T-dependent B cell responses. We observed lower titers of high-affinity IgG and fewer antigen-specific germinal center (GC) B cells. GC B cells from chronic VNS mice exhibited altered mRNA and protein expression suggesting increased apoptosis and impaired plasma cell differentiation. Follicular dendritic cell (FDC) cluster dispersal and altered gene expression suggested poor function. The absence of acetylcholine-producing CD4 + T cells diminished these alterations. In vitro studies revealed that α7 and α9 nicotinic acetylcholine receptors (nAChRs) directly regulated B cell production of TNF, a cytokine crucial to FDC clustering. α4 nAChR inhibited coligation of CD19 to the B cell receptor, presumably decreasing B cell survival. Thus, VNS-induced GC impairment can be attributed to distinct effects of nAChRs on B cells.


  • Open Access

    Vagus nerve stimulation limits the germinal center B cell response via CD4+ T cell-derived acetylcholine

    by Izumi Kurata-Sato, Ibrahim T Mughrabi, Minakshi Rana, Michael Gerber, Yousef Al-Abed, Barbara Sherry, Stavros Zanos, Betty Diamond

    Neural signals are known to contribute to immune regulation and modulation of the innate immune response downstream of the vagus nerve has been well studied. The effects of vagus nerve activity on antibody production, however, have been largely unexplored. Here we use a chronic vagus nerve stimulation (VNS) mouse model to study the effect of vagal activation on T-dependent B cell responses. We observed lower titers of high-affinity serum IgG and fewer antigen-specific germinal center (GC) B cells in the spleen. GC B cells from chronic VNS mice expressed more active caspase-3 and exhibited an altered gene expression profile suggesting increased susceptibility to apoptosis and impaired maturation. Follicular dendritic cell (FDC) cluster dispersal and altered FDC gene expression suggested poor FDC function. These alterations were diminished in the absence of a subset of acetylcholine-producing CD4+ T cells. In vitro studies revealed that α7 and α9 nicotinic acetylcholine receptors (nAChRs) directly regulated B cell production of TNF, a cytokine crucial to FDC clustering. Engagement of the α4 nAChR subunit on B cells impaired Akt phosphorylation, presumably decreasing B cell survival. Thus, VNS-induced GC impairment can be attributed, at least in part, to the effect of acetylcholine on B cell intrinsic pathways, resulting in hindered B cell survival and maturation and leading to an alteration in FDC function. Our findings identify a potential therapeutic target to prevent immunosuppression in conditions associated with increased vagal activity.

  • Open Access

    Voltammetry in the spleen assesses real-time immunomodulatory norepinephrine release elicited by autonomic neurostimulation

    by Ibrahim T. Mughrabi, Michael Gerber, Naveen Jayaprakash, Santhoshi P. Palandira, Yousef Al-Abed, Timir Datta-Chaudhuri, Corey Smith, Valentin A. Pavlov, Stavros Zanos

    The noradrenergic innervation of the spleen is implicated in the autonomic control of inflammation and has been the target of neurostimulation therapies for inflammatory diseases. However, there is no real-time marker of its successful activation, which hinders the development of anti-inflammatory neurostimulation therapies and mechanistic studies in anti-inflammatory neural circuits. In mice, we performed fast-scan cyclic voltammetry (FSCV) in the spleen during intravenous injections of norepinephrine (NE), and during stimulation of the vagus, splanchnic, or splenic nerves. We defined the stimulus-elicited charge generated at the oxidation potential for NE (~ 0.88 V) as the “NE voltammetry signal” and quantified the dependence of the signal on NE dose and intensity of neurostimulation. We correlated the NE voltammetry signal with the anti-inflammatory effect of splenic nerve stimulation (SpNS) in a model of lipopolysaccharide- (LPS) induced endotoxemia, quantified as suppression of TNF release. The NE voltammetry signal is proportional to the estimated peak NE blood concentration, with 0.1 μg/mL detection threshold. In response to SpNS, the signal increases within seconds, returns to baseline minutes later, and is blocked by interventions that deplete NE or inhibit NE release. The signal is elicited by efferent, but not afferent, electrical or optogenetic vagus nerve stimulation, and by splanchnic nerve stimulation. The magnitude of the signal during SpNS is inversely correlated with subsequent TNF suppression in endotoxemia and explains 40% of the variance in TNF measurements. FSCV in the spleen provides a marker for real-time monitoring of anti-inflammatory activation of the splenic innervation during autonomic stimulation.


  • Open Access

    Ultrasound neuromodulation of an anti-inflammatory pathway at the spleen produces sustained improvement of experimental pulmonary hypertension

    by Stefanos Zafeiropoulos, Umair Ahmed, Alexandra Bekiaridou, Ibrahim T Mughrabi, Naveen Jayaprakash, Nafiseh Saleknezhad, Chrystal Chadwick, Anna Daytz, Izumi Sato, Yemil Atish-Fregoso, et al.

    Rationale Chronic inflammation is pathogenically implicated in pulmonary arterial hypertension (PAH), however, it has not been adequately targeted therapeutically. Objectives We investigated whether neuromodulation of an anti-inflammatory neuroimmune pathway using noninvasive, focused ultrasound stimulation of the spleen (sFUS) can improve experimental pulmonary hypertension (PH). Methods PH was induced in rats by SU5416 (20 mg/kg SQ) injection, followed by 21 (or 35) days of hypoxia (10% FiO2). Animals were randomized to receive either daily, 12-min-long sessions of sFUS or sham-stimulation, for 14 days. Invasive hemodynamics, echocardiography, autonomic function parameters, lung and heart histology/immunohistochemistry, and lung single-cell-RNA sequencing were performed after treatment to assess effects of sFUS. Results Compared to sham, sFUS treatment reduces right ventricular (RV) systolic pressure by 25-30%; it improves RV function and indices of autonomic function. sFUS treatment reduces wall thickness in small pulmonary arterioles, suppresses inflammatory cell infiltration in lungs and RV fibrosis and hypertrophy, and lowers serum levels of brain natriuretic peptide. Beneficial effects persist for weeks after sFUS treatment discontinuation and are more robust when treatment is initiated earlier and delivered for longer. Selective ablation of the splenic nerve abolishes the therapeutic benefits of sFUS. sFUS treatment downregulates several inflammatory genes and pathways in nonclassical and classical monocytes, and macrophages in the lung; differentially expressed genes in those cell types are significantly enriched for genes associated with human PAH. Conclusions Noninvasive, sFUS treatment causes sustained improvement of hemodynamic, autonomic, laboratory and pathological manifestations of experimental PH, and downregulates inflammatory genes and pathways in the lung, many of which are relevant in human disease.


  • Open Access

    Galantamine attenuates autoinflammation in a mouse model of familial mediterranean fever

    by Ibrahim T. Mughrabi, Mahendar Ochani, Mirza Tanovic, Ping Wang, Betty Diamond, Barbara Sherry, Valentin A. Pavlov, Seza Ozen, Daniel L. Kastner, Jae Jin Chae, et al.

    Background: Autoinflammatory diseases, a diverse group of inherited conditions characterized by excessive innate immune activation, have limited therapeutic options. Neuroimmune circuits of the inflammatory reflex control innate immune overactivation and can be stimulated to treat disease using the acetylcholinesterase inhibitor galantamine. Methods: We tested the efficacy of galantamine in a rodent model of the prototypical autoinflammatory disease familial Mediterranean fever (FMF). Multiple chronic disease markers were evaluated in animals that received long-term galantamine treatment compared to vehicle. Results: Long-term treatment with galantamine attenuated the associated splenomegaly and anemia which are characteristic features of this disease. Further, treatment reduced inflammatory cell infiltration into affected organs and a subcutaneous air pouch. Conclusions: These findings suggest that galantamine attenuates chronic inflammation in this mouse model of FMF. Further research is warranted to explore the therapeutic potential of galantamine in FMF and other autoinflammatory diseases.


  • Open Access

    Galantamine Attenuates Autoinflammation in a Mouse Model of Familial Mediterranean Fever

    by Ibrahim T. Mughrabi, Mahendar Ochani, Mirza Tanovic, Ping Wang, Betty Diamond, Barbara Sherry, Valentin A. Pavlov, Seza Ozen, Daniel L. Kastner, Jae Jin Chae, et al.

    Autoinflammatory diseases, a diverse group of inherited conditions characterized by excessive innate immune activation, have limited therapeutic options. Neuroimmune circuits of the inflammatory reflex control innate immune overactivation and can be stimulated to treat disease using the acetylcholinesterase inhibitor galantamine. Here, we tested the efficacy of galantamine in a rodent model of the prototypical autoinflammatory disease familial Mediterranean fever (FMF). Long-term treatment with galantamine attenuated the associated splenomegaly, amyloidosis, and anemia that are characteristic features of this disease. Further, treatment reduced inflammatory cell infiltration into affected organs and a subcutaneous air pouch. These findings suggest that galantamine attenuates chronic inflammation in this mouse model of FMF. Further research is warranted to explore the therapeutic potential of galantamine in FMF and other autoinflammatory diseases.